A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...

Potential rivals to the drug include Roche/Dicerna’s xalnesiran and Johnson & Johnson/Arrowhead’s ARO-HBV, which are both also in mid-stage testing. Merck KGaA is shaping up to take on Daiichi ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

The "Digital PCR Market - A Global and Regional Analysis: Focus on Type, Application, End User, and Country Analysis - ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...

DNA testing of 14 individuals buried in the ancient Roman city of Pompeii has shown their sex and ethnic background is different to what earlier archaeologists assumed. Nuclear and mitochondrial ...

Beta blockers are go-to meds for many people who've survived a heart attack, but might not be needed for patients whose ...